Oncology Central

Cell-free DNA for the detection of pancreatic, liver and upper gastrointestinal cancers: has progress been made?


Detecting alterations in blood cell-free DNA (cfDNA) is hoped to be a novel, noninvasive method for diagnosing, prognosing and monitoring cancer patients. Several studies have assessed the usefulness of measuring tumor-specific genetic and epigenetic changes of cfDNA, such as loss of heterozygosity, frequency of mutations, alterations of microsatellites and the methylation of genes in patient blood samples.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.